New to The Street announced a comprehensive media partnership with Lantern Pharma (LTRN). The collaboration includes a full-year series of national TV interviews, commercial campaigns, earned media placements, and iconic billboard exposure across New York City’s Financial District and Times Square. The partnership will also integrate non-deal roadshow coverage, bringing Lantern Pharma’s story directly to institutional and accredited investor audiences across key U.S. markets. Lantern Pharma will be featured on New to The Street’s nationally syndicated broadcasts airing on Bloomberg Television and Fox Business Network as sponsored programming, alongside coverage across the show’s digital, social, and outdoor media platforms.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN:
- Lantern Pharma presents clinical data from LP-284
- Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors
- Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment?
- Lantern Pharma’s LP-184 Study: A Potential Game-Changer in Cancer Treatment
- Lantern Pharma Holds Annual Stockholders Meeting